Zylox-Tonbridge to Acquire Equity Interest in A European Medical Device Company to Accelerate Expansion in the Global MedTech Market
Zylox-Tonbridge to Acquire Equity Interest in A European Medical Device Company to Accelerate Expansion in the Global MedTech Market |
| [15-January-2026] |
Marks a major milestone in Zylox-Tonbridge's long-term commitment to global expansion Builds an integrated global commercialization platform to accelerate Zylox-Tonbridge's adoption of innovative vascular solutions worldwide Delivers Zylox-Tonbridge's manufacturing and operational synergies across Germany and China Fully unlocks Zylox-Tonbridge's high-efficiency R&D capabilities HANGZHOU, China and BERLIN, Jan. 16, 2026 /PRNewswire/ -- Zylox-Tonbridge (HKEX:2190), a Hong Kong-listed medical technology company focused on neuro-and peripheral vascular interventional products and solutions, today announced that it has entered into a definitive agreement to acquire a Germany-based medical technology company, Optimed Medizinische Instrumente GmbH ("Optimed"), specializing in research and development, production and distribution of medical devices for minimally invasive therapy worldwide, in multiple steps. Under the terms of the agreement, Zylox-Tonbridge has the option to acquire the entire equity interest in Optimed from its existing shareholders. Optimed is a leading medical technology company specializing in minimally invasive vascular and endourology devices. Over nearly three decades, Optimed has developed an extensive sales and service network spanning more than 70 countries worldwide and has developed long-standing relationships with physicians and key opinion leaders in Europe and other key markets. Optimed has one of the most comprehensive product portfolios in the peripheral venous stenting market, including specialized devices for the iliofemoral veins, the iliac bifurcation and the vena cava. Optimed's dedicated venous stents are supported by high-evidence clinical trials such as the sinus-Venous, is supported by robust clinical evidence from STEVECO, the first prospective, randomized, multicenter trial in this chronic deep venous obstruction setting, which demonstrated significant improvements in quality of life and clinical severity compared with conservative treatment. The acquisition of Optimed accelerates Zylox-Tonbridge's global expansion by establishing a unified platform spanning research and development, manufacturing, and commercialization. By integrating both companies' sales networks and leveraging Optimed's long-standing relationships with European clinical experts, Zylox-Tonbridge will be positioned to bring products to market more efficiently and expand its global reach. Furthermore, this partnership is also expected to generate significant operational synergies, supported by an expanded manufacturing base in Germany to ensure a high-quality, reliable supply of innovative medical solutions for European and global markets. Following the closing of the transaction, Zylox-Tonbridge will integrate its sales, marketing, and customer service teams with those of Optimed to create one unified global commercial organization. Rüdiger Hausherr will continue to serve as Chief Executive Officer of Optimed and will report to Jonathon Zhong Zhao, Chairman and Chief Executive Officer of Zylox-Tonbridge. Dr. Jonathon Zhong Zhao, Chairman and Chief Executive Officer of Zylox-Tonbridge, said, "This acquisition marks an important milestone in Zylox-Tonbridge's global strategy, enabling the Company to leverage a broader European-based platform to accelerate its global expansion. We are very pleased to welcome Optimed to the Zylox-Tonbridge Group and look forward to combining our complementary product portfolios and manufacturing platforms to bring high-quality, innovative and affordable solutions to more patients and physicians worldwide, while driving the Company's next phase of growth." Rüdiger Hausherr, Chief Executive Officer of Optimed, said, "For nearly three decades, Optimed has worked closely with physicians to build a trusted brand in vascular and endourology care. While Optimed has established a strong global position, rapidly evolving customer needs and healthcare dynamics mean that maintaining the status quo is no longer sufficient. Over the past months, we have established a clear and aligned strategic vision with Zylox-Tonbridge. By combining Zylox-Tonbridge's strong R&D and manufacturing capabilities with our global footprint, we are creating a solid platform to accelerate the next phase of growth and deliver even greater value to clinicians and patients worldwide." Hans-Henning von Oertzen, Founder and Managing Partner of Westlake Partners, said, "Since investing in Optimed, we have worked closely with the team to broaden its product portfolio, strengthen its clinical relationships and expand its international footprint, helping it become a leader in minimally invasive vascular and endourology solutions. Zylox-Tonbridge is a fast-growing multinational medical technology company with deep roots in China and highly regarded R&D, manufacturing and global commercialization capabilities. We look forward to seeing the two companies unlock new opportunities and shape an even stronger future together for physicians and patients worldwide." Transaction Benefits
About Zylox-Tonbridge Zylox-Tonbridge Medical Technology Co., Ltd. ("Zylox-Tonbridge", HKEX: 2190) is a medical technology company dedicated to the innovative research and development, manufacturing and commercialization of medical devices in the field of vascular intervention. Founded in 2012, the Company is headquartered in Hangzhou, China. As an integrated medical device company supported by in-house R&D and manufacturing capabilities, proprietary technology platforms and strong commercialization capabilities, Zylox-Tonbridge adheres to the brand philosophy of "Innovation for Quality Life". The Company is committed to providing patients with high-quality, affordable medical devices and services, enabling more people to benefit from the improved quality of life brought by advanced medical technology. For more information, please visit our official website at https://www.zyloxtb.com/. About Optimed Medizinische Instrumente GmbH Optimed, based in Ettlingen, Germany, has been dedicated to the research, development, manufacturing and global distribution of high-quality medical devices for minimally invasive therapy since 1996. Backed by a strong track record of innovation, Optimed is widely recognized as a global leader in venous stenting. With a dedicated team of approximately 200 professionals across its headquarters, production sites, and international sales organization, the Company ensures seamless operations and delivers exceptional service to its global customers. With an extensive sales and service network spanning more than 70 countries, Optimed delivers reliable solutions that help advance patient care worldwide. About E-Med Solutions and Westlake Partners E-Med Solutions is held by a group of investors led by Westlake Partners, an entrepreneurial investors company. Together with a group of international and experienced entrepreneurs and corporate executives, Westlake Partners focuses on the investment in successful German mid-cap companies. One of the objectives is to establish them permanently not only in Germany and Europe but also in the biggest growing economies, such as China and North America.
| ||
Company Codes: HKEX:2190,HongKong:2190 |
View original content:
